MedTrace Logo

Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

NCT01125761 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-11-03

No results posted yet for this study

Summary

Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.

Conditions

  • Dermatitis

Interventions

DRUG

dexamethasone 0.5 mg and 1.0 mg clemastine cream

The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.

DRUG

Dexamethasone 0,5 mg cream

The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.

Sponsors & Collaborators

  • Azidus Brasil

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125761 on ClinicalTrials.gov